ENTPD1 and cancer: They have modified M1Exos with catalases to relieve tumor hypoxia and loaded them with DNA damage repair inhibitor as well as anti‐PD‐L1 nanobody, which together results in an effective remodeling of the immunosuppressive TME and finally an enhanced radiotherapy (Figure 9).[293] Wu et al. have used cancer cell‐derived exosomes to deliver POM1 (CD39 antagonist) and metformin (AMPK agonist) for targeted cancer therapy.